Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review
Trastuzumab deruxtecan (T-DXd or DS-8201), as a novel antibody–drug conjugate, has demonstrated good efficacy in HER2-positive advanced breast cancer. However, its effectiveness in treating pulmonary lymphangitic carcinomatosis (PLC) has not been previously reported. This paper presents a case of a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1574286/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Trastuzumab deruxtecan (T-DXd or DS-8201), as a novel antibody–drug conjugate, has demonstrated good efficacy in HER2-positive advanced breast cancer. However, its effectiveness in treating pulmonary lymphangitic carcinomatosis (PLC) has not been previously reported. This paper presents a case of a HER2-positive advanced breast cancer patient who experienced disease progression after treatment with trastuzumab and pertuzumab. The patient developed multiple metastases along with PLC and subsequently received T-DXd treatment, achieving 14.2 months of progression-free survival (PFS). This case is the first to reveal the therapeutic potential of T-DXd in breast cancer patients with PLC. |
|---|---|
| ISSN: | 1663-9812 |